Tiziana Life Sciences (TLSA) announced that it intends to develop its fully human anti-IL-6 receptor monoclonal antibody, TZLS-501, and related assets via a spinout into a separate publicly traded company. The company said Tiziana shareholders at the record date will retain value from TZLS-501 through the distribution in specie of shares in the new TZLS-501 listed entity. Tiziana Life Sciences considers TZLS-501 as having the potential to be a standalone business. The company intends to proceed with steps for a publicly listed immunology-focused spin-out company, centered on the IL-6 market.
"This spin-out will unlock dedicated resources for its development, while allowing us to maintain focus on intranasal foralumab as our lead program," Ivor Elrifi, CEO of Tiziana Life Sciences, said.
Shares of Tiziana Life Sciences are down 7% in pre-market trade on Tuesday.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.